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Abstract
Combining molecular dynamics (MD) in a hydrated phospholipids (DOPC) bilayer, Monte Carlo
search, and synthesis of locked nucleotide analogues we discovered that the Southern conformation
of the ribose is preferred for ligand recognition by the P2Y6 receptor. 2′-Deoxy-(S)-
methanocarbaUDP was found to be a full agonist of the receptor and displayed a 10-fold higher
potency than the corresponding flexible 2′-deoxyUDP. MD results also suggested a conformational
change of the second extracellular loop consequent to agonist binding.
P2Y receptors are a family of class A G protein-coupled receptors (GPCRs), variously activated
by extracellular purine and pyrimidine nucleotides.1,2 The family is composed of two distinct
subgroups, which differ in overall sequence similarity, mechanism of ligand recognition, and
coupling to second messengers. The P2Y1-like subgroup encompasses the P2Y1, P2Y2,
P2Y4, P2Y6, and P2Y11 receptors, which couple mainly to the stimulation of phospholipase C
(PLC) via Gq. On the other hand, the P2Y12-like subgroup encompasses the P2Y12, P2Y13,
and P2Y14 receptors, which couple mainly to the inhibition of adenylyl cyclase (AC) via Gi.
The P2Y6 receptor is the only P2Y receptor whose natural agonist is uridine-5′-diphosphate
(UDP, 1). It is the least studied subtype of the P2Y1-like subgroup, due to the lack of potent
and selective ligands. It has recently been shown that the activation of the P2Y6 receptor
induces Ca2+ and Cl− secretion in mouse trachea. Hence, P2Y6 agonists may be useful to
stimulate electrolyte transport in the airways of cystic fibrosis patients.3
It is known that the five-membered ring of the ribose moiety of nucleosides and nucleotides
can adopt a range of conformations, which can be exhaustively described by two parameters
indicative of puckering: P (phase angle of pseudorotation, schematically represented as a
pseudorotational cycle) and θ (puckering amplitude).4,5 Using conformationally-locked
nucleotide analogues, we deduced a preference for the Northern (N) hemisphere of the
pseudorotational cycle (2′-exo, 3′-endo) for the P2Y1, P2Y2, P2Y4, and P2Y11 receptors.4,6,
7,8 However, the UDP analogue 2 locked in the (N) conformation by a (N)-methanocarba
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system was found completely inactive (Figure 1).7 Hence, prior to this work, the P2Y6 receptor
has been the most elusive subtype of the P2Y1-like receptors and the conformation of the ribose
moiety of UDP required for the recognition of the ligand was not established.
Here we report the discovery of the biologically-active conformation of the sugar moiety of
UDP, which we accomplished by means of an interdisciplinary approach combining advanced
molecular modeling techniques with the synthesis of conformationally locked nucleotide
analogs. This finding represents a breakthrough toward the understanding of the biology of the
P2Y6 receptor, as it may be the key to the design of the long needed pharmacological tools.
To obtain a refined model of the P2Y6 receptor that could be exploited to identify the
conformation of the ribose moiety required for the molecular recognition of UDP, we submitted
our rhodopsin-based homology model of the receptor1 to 10 ns of molecular dynamics (MD)
in a fully hydrated phospholipid (dioleoylphosphatidylcholine, DOPC) bilayer, which was
constructed around the receptor according to a modification of the stepwise procedure
developed by Woolf and Roux.9 The simulated system was composed of the P2Y6 receptor,
100 DOPC molecules evenly distributed between the extracellular and the intracellular sides,
6030 water molecules, and 19 Cl− ions, which were added in order to neutralize the total charge
of the system. The simulation was conducted with the program CHARMM10 under constant
pressure and temperature conditions (P = 1 atm; T = 310 K), with periodic hexagonal boundary
conditions applied in all directions, to simulate a multilayer of infinite membranes.
To date, bovine rhodopsin is the only GPCR for which an experimental structure has been
elucidated, and therefore is the only suitable template for the construction of homology models
of the other members of the superfamily. Homology modeling has proven to be a very powerful
technique, even when the template and the protein to be modeled are only distantly related.
11 However, although a common general structure is likely to be shared by all GPCRs, specific
differences do exist between rhodopsin and the other receptors. In particular, many GPCRs,
including the P2Y receptors, show a different distribution of Pro residues within the 7
transmembrane (TM) domains when compared to rhodopsin, suggesting the likelihood of
conformational differences.1 Moreover, the intracellular and extracellular regions of the
GPCRs show a high variability in the amino acid sequence, which suggests a very limited
structural similarity to rhodopsin. An MD simulation of a membrane protein in a hydrated lipid
bilayer permits an unconstrained relaxation of the protein model within the context of its natural
environment, allowing the backbone and the side chains to search for a stable conformation.
In Figure 2a we report a superimposition of the P2Y6 homology model and the typical structure
occurring in the timeframe from 9.9 to 10 ns of the MD simulation. In order to facilitate the
comparison among receptors, throughout this paper we use the GPCR residue indexing system,
as explained in the supporting information. Although the overall structure of the helical bundle
was conserved throughout the MD simulation, a root mean square deviation (RMSD) of 2.70
Å was found between the backbone of the 7 TMs of the initial and the final structures. In
particular, the P2Y6 receptor contains four Pro residues, not conserved in rhodopsin, at
positions 1.36, 1.37, 2.58, and 7.40. These Pro residues caused the formation of kinks in the
upper segments of TM1, TM2, and TM7 during the MD simulation. The amphipathic helix 8
(H8), located at the cytoplasmic end of TM7, at the interface between the lipid bilayer and the
cytosolic water, remained stable throughout the trajectory (Figure 2a). Among the extracellular
regions, the second extracellular loop (EL2) has been recognized as particularly important for
the ligand recognition and for the activation of various GPCRs, including the P2Y receptors.
12,13,14 In rhodopsin, and hence in our initial homology model of the P2Y6 receptor, EL2
forms a β-hairpin parallel to the plane of the membrane, which occludes the entry to the cavity
within the helical bundle. In our MD simulation of the P2Y6 receptor, EL2 moved toward TM3
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and further up into the extracellular space, making the putative nucleotide binding site
accessible to an approaching ligand.
The typical structure of the system occurring during the timeframe from 9.9 to 10 ns of the
MD was used for the ligand docking experiments. UDP was positioned into the putative binding
pocket in line with our previously published binding mode of nucleotides at the P2Y1-like
receptors.1,4 According to this experimentally supported binding mode, the sugar moiety is
located between TM3 and TM7, the base points toward TM1 and TM2, while the diphosphate
moiety points in the direction of TM6.
A conformational analysis of the ligand inside the binding pocket, with particular attention to
the sugar puckering, was conducted by means of the Monte Carlo Multiple Minimum (MCMM)
conformational sampling as implemented in MacroModel (Schrödinger, LLC). In order to keep
the bias on the ribose puckering as low as possible, the search was seeded with one UDP
molecule in the (N) and one in the Southern ((S), 2′-endo, 3′-exo) conformation, minimized
within the binding pocket. All the torsional angles of the ligand and the side chains of the
residues within 5 Å from the ligand were subjected to the Monte Carlo search. At the same
time, the ligand was subjected to Monte Carlo rotations and translations.
The search produced ten receptor-ligand complexes compatible with our previously
published1,4 binding mode. The ten complexes fell into two distinct clusters, which identified
two overlapping binding modes of UDP within the exofacial side of the cavity delineated by
TM1, TM2, TM3, TM6, and TM7 (Figure 2b). The more external pocket (Figure 2c) could be
a meta-binding site to which the ligand binds in its path to the principal binding site. Similar
meta-binding sites have been previously hypothesized for the P2Y1 receptor.15 The meta-
binding site cluster was composed of three receptor-ligand complexes, two with UDP in the
(S) conformation and one with UDP in the (N) conformation. The more deeply buried binding
site cluster consisted of seven receptor-ligand complexes, all with UDP in the (S) conformation
(Figure 2d). Thus, our conformational search indicated a clear preference of P2Y6 for the (S)
conformation of the ribose moiety of UDP. Although UDP could bind to the meta-binding site
in the (N) conformation, the (S) conformation seemed to be exclusively required for binding
to the principal binding site.
In all the docking poses (Figure 2b–d), the phosphate moiety of UDP bound to the same
positively charged sub-pocket formed by three cationic amino acids from TM3, TM6, and
TM7, namely R103(3.29), K259(6.55), and R287(7.39). These residues, which are conserved
in all the subtypes of the P2Y1-like subgroup of the P2Y receptors, were found essential for
the activation of the P2Y1 receptor by nucleotides in site-directed mutagenesis experiments.
16 Our previous molecular modeling studies suggested their involvement in the coordination
of the phosphate moieties in all the P2Y1-like receptors.1 The fact that in the meta-binding site
the diphosphate moiety of UDP was already bound to the aforementioned positively-charged
pocket, suggests that the electrostatic attraction between this pocket and the negatively charged
diphosphate could be the driving force of the ligand binding process.
In the principal binding site the conserved S291(7.43) was involved in the coordination of the
2-O of the pyrimidine moiety of UDP (Figure 2). S7.43 was also found essential for the
activation of P2Y1 by nucleotides,16 and was suggested to be involved in the coordination of
the nucleobase on the basis of molecular modeling results.1 Conversely, in the meta-binding
site S291(7.43) was hydrogen bonded to Y33(1.39). Molecular modeling results had previously
suggested the importance of the H-bond between the conserved Y1.39 and S7.43 in the
stabilization of the ground state of the P2Y receptors.1 The loss of this H-bond consequent to
shifting of UDP from the meta- to the principal binding site, could play a role in the activation
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of the receptor. Mutagenesis studies aimed at further investigating this working hypothesis are
currently ongoing in our laboratories.
In order to refine the receptor-ligand interactions and to study the stability of the (S)
conformation of UDP within the receptor binding pocket, a P2Y6-UDP complex representative
of the principal binding site was submitted to 5 ns of MD in the DOPC bilayer environment.
The typical structure occurring in the timeframe from 14.9 to 15 ns of the MD simulation is
represented in Figure 2e. The interactions among the diphosphate moiety of UDP and the three
cationic residues from TM3, TM6, and TM7 remained stable throughout the 5 ns of MD. Y283
(7.35) also engaged a stable H-bond with the diphosphate. Consistently, we previously found
that Ala and Phe mutations of the corresponding residue in the P2Y1 receptor led to 10-fold
reduced affinity for the agonist 2-MeSADP.1 The role of Y7.35 in the ligand binding could
not be established in docking experiments conducted prior to MD. The 3′-OH group of UDP
established stable H-bonds, mediated by a water molecule, with K259(6.55) and,
intramolecularly, with the 5′-O. The interaction between S291(7.43) and the 2-O of UDP
remained stable throughout the simulation, and Y33(1.39) established a stable H-bond with
the 1-NH of UDP. The uracil ring was stabilized by hydrophobic interactions with the
conserved residues F106(3.32), L29(1.35), and I83(2.61).
An electrostatic interaction between R103(3.29) and the conserved D179(EL2) was stable
throughout the 10 ns of the MD of the unoccupied P2Y6 and was lost in the MD of the P2Y6-
UDP complex. In fact, R103(3.29) engaged in electrostatic interaction with the diphosphate
moiety of UDP, while D179(EL2) was repelled toward the extracellular space by the negative
charge of the ligand (Figure 2f). The R103(3.29)-D179(EL2) interaction, which seems
fundamental in the stabilization of the unoccupied P2Y6 receptor, could not be detected prior
to the MD simulation. The presence of the ligand in the P2Y6 binding pocket caused the
disruption of this interaction and a consequent substantial conformational change of EL2,
whose backbone showed an RMSD of 3.81 Å between the typical structures of the unoccupied
and occupied receptors. A movement of EL2 is associated with the activation of other GPCRs.
13,14 Previous studies suggested that the corresponding R128(3.29) and D204(EL2) of the
P2Y1 receptor are involved in the process of ligand recognition and/or receptor activation,
since in both cases a mutation to Ala highly impaired the ability of the agonist 2-MeSATP to
stimulate the receptor.12,16 Our MD simulation suggests a similar role for the corresponding
residues of the P2Y6 receptor; however, for P2Y6 as well as the other subtypes of the P2Y
receptors, this hypothesis remains to be tested using mutagenesis experiments. Besides EL2,
the backbone of the P2Y6 receptor did not show significant changes after the 5 ns of MD in
complex with the ligand. The average RMSD between the backbone of the typical structures
of the unoccupied and the occupied receptors was 1.14 Å for the TMs and 2.29 Å for the loops,
excluding EL2.
The ribose moiety of UDP maintained stable torsional angles throughout the simulation,
showing, in the final typical structure, a P of 180° and a θ of 36°, indicative a pure (S)
conformation. We have reported elsewhere the formulae to derive P and θ from the five
torsional angles of a five-membered ring.4 During the whole time of the simulation, the (S)
conformation of the ribose ring ensured the optimal fitting of the sugar moiety of UDP in the
P2Y6 binding pocket. Furthermore, it conferred to the phosphate and the nucleobase moieties
the most favorable orientation for the establishment of interactions with the residues from TM1,
TM3, TM6, and TM7 (Figure 2e).
On the basis of the molecular modeling results, we devised the synthesis of a carbocyclic
analogue of UDP locked in the (S) conformation by a (S)-methanocarba modification of the
ribose ring. The methanocarba system, introduced by Marquez and coworkers, consists of a
cyclopentane ring fused with a cyclopropane ring and can be used to constrain a pseudosugar
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ring in the (N) or the (S) conformations, depending on the position of the fusion.17 The starting
nucleoside necessary for the synthesis of the enantiomerically pure (S)-2′-deoxy-
methanocarbaUDP was readily available in our laboratories, since it was earlier synthesized
and tested for its antiviral activity by Marquez and coworkers.18 Furthermore, we inferred
from the model that the 2′-OH group, although important in the stabilization of the ligand
through an intramolecular H-bond with the 2-O, was not involved in crucial interactions with
the receptor. Therefore, we evaluated the potency and the efficacy of 2′-deoxyUDP (3) in
activation of PLC in 1321N1 astrocytoma cells stably transfected with the human P2Y6
receptor, and discovered that, although less potent than UDP (1), it maintained full agonistic
activity at the P2Y6 receptor (Table 1, Figure 1). Hence, in order to verify the modeling
predictions and to accelerate the lead discovery process we decided to synthesize the (S)-2′-
deoxy-methanocarbaUDP (10) rather than the (S)-methanocarbaUDP. The synthesis began
with the (S)-2′-deoxy-methanocarba uridine (4), which was prepared according to the
procedure previously reported by Marquez et al.18 The (S)-2′-deoxy-methanocarba uridine
(4) was treated sequentially with t-butyldiphenylsilyl chloride and dihydropyran to give the
protected uridine derivative 6. Selective deprotection of the 5′-silyl group was achieved by the
reaction of 6 with 1M tetrabutylammonium fluoride solution in tetrahydrofuran to afford 7 in
66% yield. Nucleoside 7 was sequentially phosphorylated by first reacting with di-t-butyl
N,N-diethylphosphoramidite and tetrazole followed by treatment with m-chloroperbenzoic
acid to afford the di-t-butyl phosphate derivative 8 in 45% yield. Both di-t-butyl and the THP
groups in 8 were deprotected simultaneously by using 10% trifluoroacetic acid solution to
afford the monophosphate 9 in 60% yield. The requisite diphosphorylation of 9 was achieved
by first reacting it with the 1,1′-carbonyldiimidazole, and subsequently reacting the resulting
phosphoimidazolate in situ with phosphoric acid tributylammonium salt to afford the target of
(S)-2′-deoxy-methanocarba 10 in 18% yield.
In agreement with the prediction by molecular modeling, not only was 10 found to be a full
agonist of the P2Y6 receptor, but it displayed an EC50 of 0.23 µM and proved to be 10-fold
more potent than the corresponding 2-deoxyUDP 3 (Table 1, Figure 1).
In conclusion, compound 10 represents a successful case of structure-based drug design, and
is the first example of a nucleotide locked in the (S) conformation found to activate any P2Y
subtype. The discovery of the activity of this novel locked nucleotide provides the first lead
for the development of potent and selective P2Y6 ligands, which are essential to further
characterize this receptor. The synthesis of the (S)-methanocarbaUDP, which is expected to
be more potent than its 2′-deoxy analogue is currently in progress. Through the lead
optimization process, we aim to find a good candidate for the development of a radioligand
for the P2Y6 receptor, which would prove fundamental to distinguish the processes of binding
and ligand recognition, therefore allowing further testing of the molecular modeling hypothesis
and consequently a more profound understanding of molecular determinants of the ligand
recognition, of the mechanisms involved in the receptor activation, and of the structure activity
relationships.
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Activation of the human P2Y6 receptors by uracil nucleotides. PLC activity was measured as
described in the Supporting Materials in 1321N1 human astrocytoma cells stably expressing
the receptor. The data are the means of triplicate determinations and are representative of results
obtained in three separate experiments.
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a) The P2Y6 receptor before (thin tube) and after (thick tube) MD. b) Tube representation of
P2Y6 with ten UDP molecules docked at the meta- and the principal binding sites. c & d)
Details of two complexes representative of the meta- (c) and the principal (d) binding sites. e)
Typical structure of the P2Y6-UDP complex after 5 ns of MD. f) An electrostatic interaction
between R103(3.29) and D179(EL2) is present in the unoccupied P2Y6 receptor (thin tube,
cyan carbon atoms) and is lost upon MD of the receptor-ligand complex (thick tube, brown
carbons). In the tube representations the receptor is colored according to residue positions, with
a spectrum of colors that ranges from red (N-terminus) to purple (C-terminus): TM1 is in
orange, TM2 in ochre, TM3 in yellow, TM4 in green, TM4 in cyan, TM5 in blue, TM7 in
purple.
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Reagents: (i) tert-butylchlorodiphenylsilane, imidazole, acetonitrile, r.t. (ii) dihydropyran, p-
toluene sulphonic acid, dichloromethane, r.t. (iii) tetrabutylammoniun fluoride, (1M), THF,
r.t. (iv) di-tert-butyl N,N-diethylphosphoramidite, tetrazole, THF, r.t., m-CPBA, −78°C, r.t.
(v) 10% TFA (vi) a. 1,1′-carbonyldiimidazole, DMF, b. triethylamine, MeOH, H2O. c.
tributylammonium phosphate, DMF, r.t.
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Table 1
EC50 values for stimulation of PLC in 1321N1 astrocytoma cells stably transfected with the human P2Y6 receptor.
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